Please login to the form below

Not currently logged in
Email:
Password:

Former GSK CEO joins Synthego’s advisory board

Sir Andrew Witty will expand the team’s bioinformatics expertise

Andrew WittyGenome engineering solutions provider Synthego has appointed Sir Andrew Witty to its advisory board, a role that will see him work on biological research and grow its application development and bioinformatics expertise.

Witty has previously served on the board of directors at GlaxoSmithKline (GSK) while he was chief executive officer (CEO) from 2008 – 2017.

He said: “Synthego’s vision for automating biological research will revolutionise the industry by accelerating application development and enabling machine learning based insights.

“Their recent rapid advances of the CRISPR field highlight their ability to execute on deep technology with a multidisciplinary, informatics-first approach.

“I look forward to contributing to the company’s success as the business extends further into the genome engineering market.”

Bringing more than 30 years’ experience to Synthego, Witty’s biopharma expertise ranges from product management and business development, to strategic partnerships.

Paul Dabrowski, CEO of Synthego, said: “Andrew’s broad experience in the biopharmaceutical space will help us unlock the full value of our platform and grow in key areas of the industry.

“This is part of the next step in bringing Synthego’s bioinformatics and experimental expertise to new applications and markets.

“Andrew’s appointment strengthens the company’s position as a leader in genome engineering solutions.”

22nd September 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics